Endogenous plasma N-acetylcysteine and single dose oral bioavailability from two different formulations as determined by a new analytical method.
A method to quantitate N-acetylcysteine in plasma using reductive cleavage with tributylphosphine and post-HPLC column derivatisation with omicron-phthalaldehyde is described. Using this method, endogenous average concentrations of 0.08 microM were measured in 10 volunteers participating in a crossover study to compare the bioavailability of two different formulations of N-acetylcysteine. The drug was detected in plasma for up to 12 h after administration of a single oral dose (200 mg); the Cmax values were up to 20 times the endogenous levels. The sensitivity and selectivity of the method should thus enable the behaviour of N-acetylcysteine after oral administration to be properly described and bioavailability studies to be performed.
Gabard
B
B
Biopharmaceutical Department, Spirig AG, Egerkingen, Switzerland.
Mascher
H
H
D000111:Acetylcysteine / Q000097:blood* / Q000493:pharmacokinetics; D000284:Administration, Oral; D000328:Adult; D001682:Biological Availability; D002851:Chromatography, High Pressure Liquid / Q000379:methods; D004304:Dosage Forms; D006801:Humans; D008297:Male; D012680:Sensitivity and Specificity
D004304:Dosage Forms; D000111:Acetylcysteine